BR112016027818A2 - composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b. - Google Patents

composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b.

Info

Publication number
BR112016027818A2
BR112016027818A2 BR112016027818A BR112016027818A BR112016027818A2 BR 112016027818 A2 BR112016027818 A2 BR 112016027818A2 BR 112016027818 A BR112016027818 A BR 112016027818A BR 112016027818 A BR112016027818 A BR 112016027818A BR 112016027818 A2 BR112016027818 A2 BR 112016027818A2
Authority
BR
Brazil
Prior art keywords
virus
cells
blood plasma
plasma products
protein compositions
Prior art date
Application number
BR112016027818A
Other languages
English (en)
Inventor
Hoang Klen
Original Assignee
Rare Antibody Antigen Supply Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54699755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016027818(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rare Antibody Antigen Supply Inc filed Critical Rare Antibody Antigen Supply Inc
Publication of BR112016027818A2 publication Critical patent/BR112016027818A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

a presente invenção se refere a produtos de plasma sanguíneo purificados obtidos de fração ii+iii contendo proteínas em concentrações úteis para o tratamento de várias doenças e infecções incluindo vírus da hepatite b. também são descritos métodos de fabricação e tratamento. os produtos purificados de plasma de sangue regulam níveis de células imunes e suas proteínas nos órgãos e sangue periférico dos indivíduos tratados. exemplos de células imunes e proteínas associadas reguladas pelos produtos purificados de plasma de sangue incluem níveis de cd62l em células t, células t cd4+, cd8+, cd28+ e foxp3+, bem como granulócitos e macrófagos.
BR112016027818A 2014-05-28 2015-05-28 composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b. BR112016027818A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462003664P 2014-05-28 2014-05-28
PCT/US2015/032807 WO2015184050A1 (en) 2014-05-28 2015-05-28 Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus

Publications (1)

Publication Number Publication Date
BR112016027818A2 true BR112016027818A2 (pt) 2017-10-24

Family

ID=54699755

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016027818A BR112016027818A2 (pt) 2014-05-28 2015-05-28 composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b.

Country Status (10)

Country Link
EP (1) EP3148574B1 (pt)
JP (1) JP2017525752A (pt)
CN (1) CN107106664A (pt)
AU (1) AU2015266997A1 (pt)
BR (1) BR112016027818A2 (pt)
CA (1) CA2949994A1 (pt)
ES (1) ES2878043T3 (pt)
MX (1) MX2016015574A (pt)
RU (1) RU2016151761A (pt)
WO (1) WO2015184050A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184050A1 (en) 2014-05-28 2015-12-03 Rare Antibody Antigen Supply, Inc. Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus
WO2016161422A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang A method of manufacturing and purifiying prothrombin complex concentrate from fraction iii for intraveneous injection and a method of curing and preventing hemophilia a with inhibitors or hempophilia b patients infected with hiv-1 and hiv-2
US20160289300A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang Method of manufacturing intravenous immunoglobulin from fraction iii

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
TWI532498B (zh) * 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CA2639003A1 (en) 2008-08-20 2010-02-20 Canadian Blood Services Inhibition of fc.gamma.r-mediated phagocytosis with reduced immunoglobulin preparations
KR20130070576A (ko) * 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
EP2569332B1 (en) * 2010-05-14 2019-01-09 The Regents of the University of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
WO2015184050A1 (en) 2014-05-28 2015-12-03 Rare Antibody Antigen Supply, Inc. Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus
TW201335181A (zh) 2012-01-31 2013-09-01 Kieu Hoang ５５種新發現的蛋白質之序列及其應用

Also Published As

Publication number Publication date
WO2015184050A1 (en) 2015-12-03
JP2017525752A (ja) 2017-09-07
ES2878043T3 (es) 2021-11-18
CA2949994A1 (en) 2015-12-03
AU2015266997A1 (en) 2016-12-08
RU2016151761A (ru) 2018-07-03
MX2016015574A (es) 2018-05-28
CN107106664A (zh) 2017-08-29
EP3148574B1 (en) 2021-04-14
EP3148574A4 (en) 2017-04-05
RU2016151761A3 (pt) 2018-12-26
EP3148574A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
AU2016277883A8 (en) PD-1-CD28 fusion proteins and their use in medicine
PH12017500803A1 (en) Anti-pd-1 antibodies
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
MD3551660T2 (ro) Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
NZ730803A (en) Methods for the preparation of ribosides
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
BR112018007538A2 (pt) células exterminadoras naturais e células ilc3 e usos das mesmas
EA201500536A1 (ru) Триазолопиразин
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
CY1123343T1 (el) Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων
UA109278C2 (uk) Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань
CY1118900T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
EA201201661A1 (ru) Новые аминопиразолохиназолины
CO6950476A2 (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
TW201613885A (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
MX2014004814A (es) Compuestos y metodos para mejorar las respuestas inmunes innatas.
EA201890572A1 (ru) Биофармацевтические композиции

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements